Propofol

Evidence Level: L2

Predicted Indications: 10

Propofol
Propofol: From General Anaesthesia and Sedation to Migraine Disorder

## Pharmacist Assessment Report

Propofol: From General Anaesthesia and Sedation to Migraine Disorder

One-Sentence Summary

Propofol is an intravenous anaesthetic and sedative that is marketed in Singapore under 6 valid registrations. The TxGNN model predicts it may be effective for migraine disorder, particularly acute and refractory migraine treated in the emergency department. Currently 3 clinical trials (1 completed Phase 2/3) and 20 publications, including several randomised trials and systematic reviews, support this direction.

Quick Overview

Item	Content
Original Indication	Not stated in the registration data compiled for this report (propofol is generally known as an intravenous anaesthetic and sedative)
Predicted New Indication	Migraine disorder
TxGNN Prediction Score	99.69%
Evidence Level	L2
Singapore Market Status	✓ Marketed
Number of Registrations	6
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data was not available in the data compiled for this report. Based on known pharmacology, propofol is a GABA-A receptor positive allosteric modulator. Enhanced GABAergic inhibition may dampen trigeminovascular and cortical hyperexcitability, both of which are involved in migraine.

Preclinical work (PMID 22390898) shows that propofol hemisuccinate suppresses cortical spreading depression. This is the proposed substrate of migraine aura and a possible trigger of headache pain. This supports a plausible mechanism for an abortive effect in refractory migraine.

The clinical rationale is also practical. Patients with severe migraine who fail first-line emergency treatments (NSAIDs, dopamine antagonists, triptans) have few good options, and sub-anaesthetic doses of propofol have been reported to help. Propofol is already used in hospitals under monitored conditions, which would make this use easier to introduce.

Other predicted indications were also reviewed. Migraine with brainstem aura is a possible extension, but its evidence is extrapolated from general migraine. The remaining predictions (Prinzmetal angina, Tourette syndrome, tendinitis, fibromyalgia and others) rest on incidental anaesthesia literature or on model scores alone, and are not supported as therapeutic uses.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01604785	Phase 2/3	Completed	74	Low-dose propofol as abortive therapy for pediatric migraine in the emergency department
NCT02485418	Not applicable	Completed	40	Low-dose propofol infusion as an abortive treatment for pediatric migraine; also assesses safe dosing limits and duration of effect
NCT02492295	Not applicable	Terminated	12	Low-dose propofol for severe refractory migraine in adults in the emergency department; stopped early with very small enrollment

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33070469	2021	RCT	Emerg Med Australas	Double-blind trial of propofol vs placebo for early resolution of acute migraine in adult ED patients
32705801	2020	Pilot RCT	Emerg Med Australas	Procedural-sedation-dose propofol vs standard therapy for initial migraine management in the ED
29456086	2018	RCT	J Emerg Med	Prospective randomised trial of low-dose propofol for pediatric migraine
35573713	2022	RCT	Arch Acad Emerg Med	Sumatriptan plus propofol compared with sumatriptan alone in acute migraine
35402989	2022	RCT	Arch Acad Emerg Med	Propofol plus granisetron vs propofol plus metoclopramide for symptom management in acute migraine
31621134	2020	Systematic review	Acad Emerg Med	Reviews the safety and efficacy of propofol for acute migraine in the ED; existing evidence is limited
41321235	2026	Guideline	Headache	2025 American Headache Society update on parenteral treatments for acute migraine in the ED
24875925	2015	Systematic review/guideline	Cephalalgia	Canadian Headache Society recommendations on migraine pain treatment in emergency settings
27454834	2016	Review	Expert Rev Neurother	Drug profile of sub-anaesthetic propofol for refractory migraine
22390898	2012	Preclinical	Neurosci Lett	Propofol hemisuccinate suppresses cortical spreading depression

Singapore Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
SIN12266P	Propofol-Lipuro Injection 1% w/v	Emulsion	Not stated in the available data
SIN11577P	Propofol 1% MCT/LCT Fresenius Emulsion for Injection or Infusion	Injection	Not stated in the available data
SIN15592P	Fresofol MCT/LCT Emulsion for Injection or Infusion in Pre-filled Syringe 2%	Injection, emulsion	Not stated in the available data
SIN13622P	Propofol-Lipuro 2% (20 mg/ml)	Emulsion	Not stated in the available data
SIN12472P	Fresofol MCT/LCT (Propofol) Emulsion for Injection or Infusion 2%	Emulsion	Not stated in the available data

A sixth registration, SIN17047P (Baxter Propofol MCT-LCT Emulsion for Injection or Infusion 1% w/v, injection/emulsion), is also valid.

Safety Considerations

Disease associations flagged in the knowledge graph (these are model-derived contraindication links, not label text): epilepsy, hypotensive disorder, respiratory failure, intracranial arteriosclerosis, inherited lipid metabolism disorder and familial hyperlipidaemia.
Drug Interactions: 100 interactions were identified. The ones shown are mostly of moderate severity, and one is minor (metronidazole). Examples include:
- Opioids: morphine (including liposomal), opium
- Antiemetics: ondansetron, granisetron, dolasetron
- Gastrointestinal agents: famotidine, loperamide, cisapride, and laxatives such as bisacodyl, lactulose, lactitol, magnesium citrate, magnesium hydroxide, castor oil, glycerin and mineral oil
- Antibiotics: clarithromycin, levofloxacin
Several of these (ondansetron, granisetron, dolasetron, cisapride, clarithromycin, levofloxacin) are agents commonly associated with QT prolongation, which is relevant in an emergency setting where antiemetics are often co-administered. Please verify this against the interaction source before relying on it.
A case-report signal of anaesthesia-related coronary spasm was also found in the literature (Prinzmetal angina search); it is a safety signal rather than evidence of benefit.

Please refer to the package insert for warnings and contraindications, as label-based safety data was not available.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: One completed Phase 2/3 trial in paediatric migraine, several randomised trials in adults and children, and systematic reviews support the use of low-dose propofol for refractory acute migraine in the emergency department. A plausible GABAergic and cortical spreading depression mechanism adds support. However, the trials are small and the existing reviews describe the evidence as limited, so the evidence level is L2 and not enough for an unrestricted recommendation. The other predicted indications are not supported and should stay on hold.

To proceed, the following is needed:

The package insert warnings, contraindications and approved indications from HSA, which are currently missing and are a blocking gap for safety screening
Detailed mechanism of action data (for example from DrugBank)
Confirmation of the original approved indications for the Singapore registrations
A confirmatory, adequately powered Phase 3 trial, with dose and setting defined
A guardrail protocol limited to monitored hospital or emergency settings, with trained staff, airway and haemodynamic monitoring, and dose limited to sub-anaesthetic levels
A review of the knowledge-graph disease associations (epilepsy, hypotension, respiratory failure and lipid disorders) and of concurrent QT-prolonging drugs before use
Confirmation of whether the sub-anaesthetic migraine dose falls outside the approved labelling, and whether a new indication application would be required in Singapore
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.